MÚLTIPLOS EPISÓDIOS DE INFARTO AGUDO DO MIOCÁRDIO APÓS USO DE ANTICOAGULANTE - RELATO DE CASO by Clivatti, Gustavo Moreira et al.
 REVISTA MÉDICA DA UFPR ISSN 2358-193x 
ISSN eletrônico 2447-3308 
  DOI 10.5380/rmu.v3i3.48266 
 
Rev. Med. UFPR 3(3):148-152 
148 
 
 
MÚLTIPLOS EPISÓDIOS DE INFARTO AGUDO DO MIOCÁRDIO 
APÓS USO DE ANTICOAGULANTE -  RELATO DE CASO 
MULTIPLE ACUTE MYOCARDIAL INFARCTION EPISODES AFTER 
ANTICOAGULANT USE - CASE REPORT 
 
Gustavo Moreira Cl ivatt i1;  João Pedro Pereira da Cunha2; Gustavo Lenci Marques3; Caio Cesar 
Cervi  Lagana2; Luciana de Cerjat Bernardes Pereira da Cunha4; Gibran Avel ino Frandoloso4;  
RESUMO 
OBJETIVO: Descrever um caso de paciente com trombocitopenia induzida por heparina (TIH) tipo II, que se manifestou através 
de consecutivos quadros de infartos agudos do miocárdio. RELATO DE CASO: Trata-se de uma paciente do sexo feminino, 70 
anos, admitida no HC-UFPR por quadro de infarto agudo do miocárdio (IAM), duas semanas após internamento hospitalar por 
pneumonia e insuficiência cardíaca descompensada, manejadas com antibioticoterapia, heparina e diuréticos. Evoluiu com 
quadro de plaquetopenia a esclarecer e dois episódios subsequentes de IAM. Após a retirada da heparina, evoluiu com 
estabilização clínica - aumento do número de plaquetas, sem novos eventos trombótico e regularização dos testes laboratoriais. 
Recebeu alta hospitalar e, no retorno ambulatorial, apresentou anticorpos anti-plaqueta positivos e uma revisão de prontuário 
com história de múltiplas exposições a heparinas não fracionada e de baixo peso molecular. CONCLUSÃO: Diante do grande 
número de pacientes expostos à heparina, seus principais efeitos colaterais, dentre os quais a TIH, precisam ser conhecidos. 
Deve-se atentar para a possibilidade de a heparina possuir associação causal com IAM, quando associado à trombocitopenia, 
visto que a tendência nessas situações é de se manter a medicação a fim de evitar quadros trombóticos futuros. 
Descritores: heparina; infarto do miocárdio; trombocitopenia. 
 
ABSTRACT 
OBJECTIVE: Report a case of patient with heparin induced thrombocytopenia (HIT) type II, which was expressed through 
consecutive episodes of acute myocardial infarction. CASE REPORT: A 70-year-old woman was admitted to hospital care due 
to an episode of acute myocardial infarction two weeks after hospitalization for pneumonia and decompensated heart failure, 
when she was managed with antibiotics, heparin and diuretics. She evolved with thrombocytopenia and two subsequent 
episodes of acute myocardial infarction. After discontinuing heparin, she progressed with clinical stabilization - an increase of 
platelets, without new thrombotic frames and regularization of laboratory tests. Patient was then discharged and during 
outpatient follow showed positive anti-platelet antibodies and a retrospective analysis of multiple exposures to unfractionated 
and low molecular weight heparins. CONCLUSION: Considering the large number of patients exposed to heparin, its major side 
effects must be known. Care must be taken to the possibly of heparin be a trigger to procoagulant state, resulting in acute 
myocardial infarction, for example, since a trend in these situations is to maintain the drug to prevent future thrombotic 
episodes. 
 Keywords: heparin; myocardial infarction; thrombocytopenia.
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Figure 1:  Pré-hospita lar eletrocardiogram presenting infarction wi th ST-segment elevation.  
INTRODUCTION 
 
 Heparin induced thrombocytopenia (HIT) is a 
major adverse drug reaction of heparin, which occurs in 
about 5% of patients exposed to the drug. It is a result of 
antibodies production against a complex of heparin and 
platelet factor 4 (PF4), that activates platelet, leading to 
formation of arterial and venous thrombi1. 
HIT can be classified in two distinct forms: type I 
and type II. HIT type I presents a mild and transient 
decrease in platelet count, that occurs within 48-72 hours 
of heparin treatment, without clinical implications, 
returning to normal spontaneously. HIT type II has a clinical 
presentation of thrombosis and thrombocytopenia, and this 
risk of thrombus formation exists until heparin is 
metabolized, excreted and another anticoagulant is set 
up2. 
The aim of this case report is describe an event of 
heparin induced thrombocytopenia type II in a patient 
manifesting consecutive frames of acute myocardial 
infarction, and perform literature review to emphasize 
diagnosis and initial treatment of this affection.  
 
CASE REPORT 
 
 A 70-year-old female with hypertension was 
complaining of chest pain at pre-hospital care. An 
electrocardiogram was performed, showing acute 
myocardial infarction with ST-segment elevation (Figure 1). 
She received acetylsalicylic acid (ASA) 200mg, 
unfractionated heparin 5000 IU subcutaneously, 
simvastatin 40 mg, isosorbide dinitrate 5 mg sublingual 
tablet, oxygen therapy 100% 2L/min. The patient was 
referred to coronary care unit to manage this clinical 
condition. 
At admission, the patient was normotensive, 
afebrile, eupneic, with a heart rate of 85 beats/min and 
90% oxygen saturation on room air. A complete physical  
examination revealed no pertinent findings, except for fine 
inspiratory bibasilar crackles. Laboratory tests were 
performed revealing metabolic alkalosis, thrombocytopenia 
(30,000 platelets count, Normal Value - NV - 150-
400,000/mm³), international normalized ratio of 
prothrombin time (INR) 1.47 (NV 0.9-1.2),  creatine kinase 
(CK) 1,442 U/L (NV 24-200 U/L), CK-MB 350 ng/mL (NV 0-
5 ng/mL) and troponin I 50,000 ng/mL (NV 0-0.5 ng/mL). 
Her medical history included: essential arterial 
hypertension for 10 years; hyperurecemia; and 
cholecystectomy 12 years ago. A recent hospitalization was 
reported (2 weeks ago) for pneumonia and decompensated 
cardiac failure. She was treated with antibiotic therapy, 
prophylatic heparin and diuretics. The patient denied 
previous alcohol consumption, but she stated a 60 pack-
year smoking history (quit 1 year ago). 
Immediately the patient was sent to the 
Hemodynamics and Interventionist Cardiology Sector, 
where clopidogrel therapy was initiated and a coronary-
stent was placed at proximal third of right artery, without 
complications. In addition, a distal trunk lesion of 30% was 
diagnosed. After procedure, she was referred to the 
Coronary Unit and treated with aspirin 100mg/day, 
clopidogrel 75 mg/day and enoxaparin (prophylatic dose). 
After stabilization, she was moved to cardiology 
ward to proceed investigation of thrombocytopenia and 
management of heart failure. On the sixth day of 
hospitalization, she developed epigastric pain, nausea and 
dyspnea at rest. A new electrocardiogram was performed, 
showing new ST segment elevation at inferior walls and V5-
V6. 
Patient was referred back to Hemodynamics 
Sector. Right coronary presented many filling holes - large 
thrombus sized 7-8 cm (Figure 2); circumflex with 80% 
residual lesions; and 30% in tronco left coronary. Because 
of atypic injury, it was chosen not to carry out intervention 
with stent. It was also detected thrombus in the left 
ventricular apex, inferoapical akinesia and inferior medial 
hypokinesia in left ventricle. 
Medical management was chosen with ASA, 
ticagrelor and tirofiban (for 48 hours). During this period, a 
slight increase in platelets count was shown, reaching 
40,000 platelets.  
On ninth day of hospitalization, she presented 
fever with a diagnosis with sepsis of unknown origin, 
isolating Enterococcus faecium in blood culture, and she 
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Figure 3:  Electrocardiogram with new ST-segment elevation. 
was treated with ampicilin. On the third day of antibiotics, 
she presented a new episode of chest pain, nausea and 
sweating. Electrocardiogram was performed, showing a 
new ST-segment elevation (Figure 3). 
Figure 2: Coronary Angiography on sixth day of 
hospital ization. 
Conservative therapy was again indicated, using 
Tirofibran, Ticagrelor, ASA, and enoxaparin full dose. Three 
days later, hemoglobin decreased by 3.4 points and 
platelet count was 28,000. Computerized tomography was 
performed due to retroperitoneal hematoma suspicion, 
since no bleeding exteriorization was seen. It showed 
thrombosis involving right branch of portal vein, splenic 
vein, right hepatic vein and right lower lobe branch of 
pulmonary artery, determining perfusion defects of liver 
and spleen compatible with infarctions. A new 
catheterization three days later was carried out showing no 
lesions in right coronary. 
After clinical stabilization, she was referred to the 
Internal Medicine Department, for conclusion of clinical 
management and investigation of thrombophilia. Warfarin 
was introduced and research for thrombophila was 
negative. Echocardiogram showed left atrium of 42 mm, 
left ventricle of 40 mm, ejection fraction of 58% and 
normal internal dimension of left ventricle, with inferior and 
lateral hypokinesia and appropriate global systolic function. 
With prothrombin activation time on target, enoxaparin was 
suspended. During five days, the platelet count evolved 
from 74,000 to 220,000 at hospital discharge.  
Reviewing patient’s medical history and previous 
hospitalar admission in another institution, we found out 
unfractionated heparin use as prophylaxis of deep vein 
thrombosis. At follow-up, she showed positive anti-platelet 
antibodies and normal platelet count using warfarin. 
Patient remained clinically stable, with no further new 
thrombotic events. 
 
DISCUSSÃO 
 
Defined as an adverse drug reaction, HIT is 
characterized by thrombocytopenia and hight risk of 
arterial or venous thrombosis3. It can lead to hight 
morbidity, with 10% of disability and it is fatal in 5-10% of 
cases4. About 8% of patients produces antibodies of HIT 
when treated with heparin. (4) However, less than 10% of 
these patients will develop HIT and lower proportions 
symptomatic thrombosis5.  
Risk factors include: (a) unfractionated heparin 
(UFH), (b) bovine UFH, (c) therapeutic doses, (d) long term 
use (over 5 days), (e) female (2:1), (f) elderly, (g) 
postoperative7.  
HIT type II occurs in approximately 1% to 3% of 
patients exposed to heparin8. It is a immune disorder which 
leads to an increased risk of 20 to 40 times of arterial and 
venous tromboses9. Originally, heparin and platelet factor 4 
(PF4) (a cytokine stored in alpha granules of platelets) are 
avoid of immunogenicity. However, when both are bound 
result to an antigenic macromolecule that bind on 
activated platelets surface. Thus, there is a conformational 
change that stimulates production of immunoglobulin G 
(IgG)10. The binding of IgG to the neo-antingen heparin-PF4 
surface leads to a process of self-amplif ication inducing 
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Table 1: “4  T score” 
severe platelet activation and the release of procoagulant 
factors, which results in intravascular thrombogenesis. 
Moreover, these immune complexes interact with 
monocytes and endothelial cells causing endothelial 
damage and tissue factor expression. By heparin 
metabolization, antibodies will also be extinguished, 
becoming undetectable 3-4 months later11.  
HIT type 2 occurs in approximately 1-3% of 
patients exposed to the drug8. It is an immune disorder, 
leading to a 20 fold increase risk of arterial and venous 
thromboses9. Originally, heparin and platelet factor 4 (PF4), 
a cytokine stored in platelets alpha granules, are devoid of 
immunogenicity. However, when bounded they result to an 
antigenic macromolecule that can bind on the surface of 
activated platelets.  With that goes a conformational 
change that stimulates immunoglobulin G (IgG) 
production10.  
HIT can present it clinical manifestation with a 
fast onset in 25% of patients, decreasing abruptly platelet 
count after few hours of exposure to heparin6.  This form is 
attributed to prior immunization by exposure on the last 
100 previous days (residual circulation of HIT antibodies). 
Although uncommon, a delayed onset - after 40 day - is 
another form of presentation. At last, the most common 
(65% of patients) is thrombocytopenia after 5-10 days of 
exposure to heparin12. 
About 50% to 75% of patients will develop 
thrombosis if untreated. The risk is positively correlated 
with thrombocytopenia severity, predicting a poor 
diagnosis7. Among complications, venous thrombosis 
(17%-55%) and arterial thrombosis (3%-10%) can manifest 
as critical organ ischemia. Others complications are stroke, 
pulmonary embolism and acute myocardial infarction7. 
HIT may be diagnosed by a clinical scoring 
system. It is a pretest called “four T’s”, developed in 
200313 and published in 200614 by Warkentin. This score 
is composed by thrombocytopenia, time, thrombosis and 
other causes for thrombocytopenia (table 1)1. Scoring can 
lead to three estimate probability: low (score of 0-3), 
intermediate (score of 4-5) and high risk (score of 6-8). (1) 
To confirm diagnosis, laboratory testing may be performed: 
washed platelet activation assays and commercial 
PF4/polyanion enzyme immunoassays (EIAs), both 
sensitive for detecting clinically relevant HIT antibodies. 
The gold standard test, Serotonin release assay (SRA), has 
high specificity and sensitively for HIT15.  
Treatment is mandatory when high suspicion or 
confirmation of HIT. The principles are: (a) stop use and 
avoid any form of heparin; (b) start any anticoagulant non-
heparin; (c) add warfarin after substantial platelet recovery 
(if warfarin has already begun, vitamin K must be used); (d) 
search for HIT antibodies; (e) investigate thrombosis of 
lower extremities and deep vein thrombosis; (f) avoid 
prophylactic platelet transfusion1. 
 
CONCLUSION 
 
Considering the large number of patients exposed 
to heparin, its major side effects must be known. HIT type II 
should be considered as differential diagnosis in patients 
with myocardial infarction and thrombocytopenia, since 
heparin use must be avoided and a specific therapeutic 
promptly applied.  
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